CG Oncology

CGON

Market cap $2.73B

Overview Fund Activity

35.76 USD

+1.16

3.35%

At close Updated Sep 16, 4:00 PM EDT

Pre-market

After hours

35.76

0.00

0%

1 day

3.35%

5 days

5.86%

1 month

36.85%

3 months

40.46%

6 months

29.24%

Year to date

23.44%

1 year

-3.35%

5 years

-3.79%

10 years

-3.79%

About: CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

Employees: 113

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

0

Analysts bullish %

of 6 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

175% more call options, than puts

Call options by funds: $21.7M | Put options by funds: $7.88M

175% more repeat investments, than reductions

Existing positions increased: 77 | Existing positions reduced: 28

105% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 19

14% more capital invested

Capital invested by funds: $1.74B [Q1] → $1.97B (+$238M) [Q2]

13% more funds holding

Funds holding: 142 [Q1] → 161 (+19) [Q2]

6.75% more ownership

Funds ownership: 92.84% [Q1] → 99.59% (+6.75%) [Q2]

10% less funds holding in top 10

Funds holding in top 10: 10 [Q1] → 9 (-1) [Q2]

See Fund Rankings

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$50

40% upside

Avg. target

$61

70% upside

High target

$75

110% upside

6 analyst ratings

6 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Andres Y. Maldonado	$75	Buy Reiterated	15 Sep 2025
Jones Trading Soumit Roy	$50	Buy Initiated	8 Sep 2025
Cantor Fitzgerald Josh Schimmer	$75	Overweight Reiterated	8 Sep 2025
Piper Sandler Kelsey Goodwin	$55	Overweight Initiated	19 Aug 2025
RBC Capital Leonid Timashev	$53	Outperform Maintained	16 Jul 2025
Morgan Stanley Jeffrey Hung	$56	Overweight Maintained	17 Jun 2025

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about CGON published over the past 30 days

CG Oncology, Inc. (CGON) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

CG Oncology, Inc. (NASDAQ:CGON ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 7:45 AM EDT Company Participants Arthur Kuan - Chairman & CEO Ambaw Bellete - President & COO Conference Call Participants Sean Laaman - Morgan Stanley, Research Division Presentation Sean Laaman Head of Healthcare Research & Equity Analyst Okay. Good morning, everyone, and welcome to Morgan Stanley Global Healthcare Conference.

CG Oncology, Inc. (CGON) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

CG Oncology Stock Signals Bullish Momentum Ahead

CG Oncology CGON has moved into Phase 2 of its 18-phase Adhishthana cycle, a critical stage that often sets the tone for early bullish momentum. Within this phase, the stock transitions into what's called the Buddhi move period, where breakouts are more likely to unfold.

CG Oncology Stock Signals Bullish Momentum Ahead

CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months

- Robust 24-month complete response (CR) rate of 41.8% observed for cretostimogene monotherapy in patients with high-risk non-muscle invasive bladder cancer (NMIBC) who are unresponsive to Bacillus Calmette Guerin (BCG) treatment -- 90% of 12-month responders remained disease free at 24 Months -- Safety profile remains consistent -

CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months

CG Oncology Completes Enrollment in PIVOT-006

– Rapid enrollment underscores high unmet need in intermediate-risk non-muscle invasive bladder cancer (NMIBC) –– One of the largest randomized phase 3 studies in this patient population will encompass broadest range of patient types per AUA/SUO Guidelines –

CG Oncology Completes Enrollment in PIVOT-006

The Motley Fool

Cg Oncology (CGON) Q2 Loss Widens 93%

Cg Oncology (CGON) Q2 Loss Widens 93%

Cg Oncology (CGON) Q2 Loss Widens 93%

CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates

- Announced best-in-disease durability data in BOND-003 Cohort C and promising early signal in Cohort P for cretostimogene grenadenorepvec at the American Urological Association Annual Meeting - - Initiated CORE-008 Cohort CX evaluating the combination of cretostimogene and gemcitabine in patients with high-risk (HR) BCG-exposed NMIBC - - Announced unanimous verdict that CG Oncology owes no future royalties or other payments to ANI Pharmaceuticals - IRVINE, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today reported financial results for the second quarter ended June 30, 2025, and provided business updates.

CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates

CG Oncology: Looking Undervalued Heading Toward FDA Submission (Upgrade)

CG Oncology, Inc.'s cretostimogene shows strong efficacy and safety in late-stage bladder cancer trials, with promising complete response rates and durable activity. The company boasts a robust cash position, providing a multi-year runway and reducing near-term dilution risk as it approaches potential commercialization. Key risk remains the lack of randomized data for FDA approval, but I view the likelihood of approval as high given the compelling clinical results.

CG Oncology: Looking Undervalued Heading Toward FDA Submission (Upgrade)

CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

IRVINE, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that Arthur Kuan, Chairman & Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference in Miami Beach, FL on Tuesday, June 10, 2025, at 11:20 am ET.

CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Zacks Investment Research

CGON Stock Rallies 27% in a Month on Bladder Cancer Study Success

CG Oncology stock surges 27% in a month following superior efficacy data from its phase III study of cretostimogene for a bladder cancer indication.

CGON Stock Rallies 27% in a Month on Bladder Cancer Study Success

Zacks Investment Research

CG Oncology, Inc. (CGON) Reports Q1 Loss, Lags Revenue Estimates

CG Oncology, Inc. (CGON) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.36 per share a year ago.

CG Oncology, Inc. (CGON) Reports Q1 Loss, Lags Revenue Estimates

See News Rankings

Charts implemented using Lightweight Charts™